<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="bgd-biotin" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">bgd-biotin</book-part-id>
      <title-group>
        <title>Biotin-Thiamine-Responsive Basal Ganglia Disease</title>
        <alt-title alt-title-type="alt-title">Synonyms: BTBGD, Biotin-Responsive Basal Ganglia Disease, Thiamine Transporter-2 Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tabarki</surname>
            <given-names>Brahim</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Prince Sultan Military and Medical City<break/>Riyadh, Saudi Arabia</aff>
          <email>btabarki@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al-Hashem</surname>
            <given-names>Amal</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Prince Sultan Military and Medical City<break/>Riyadh, Saudi Arabia</aff>
          <email>aalhashem@psmmc.med.sa</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alfadhel</surname>
            <given-names>Majid</given-names>
          </name>
          <degrees>MD, MHSc, FCCMG</degrees>
          <aff>King Abdulaziz Medical City<break/>King Saud Bin Abdulaziz University for Health Sciences<break/>Riyadh, Saudi Arabia</aff>
          <email>dralfadhel@yahoo.com</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2013-11-21" date-type="created">
          <day>21</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="biotin" document-type="chapter">Biotinidase Deficiency</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="bhd" document-type="chapter">Birt-Hogg-Dub&#x000e9; Syndrome</related-object>
      <abstract id="bgd-biotin.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Biotin-thiamine-responsive basal ganglia disease (BTBGD) is characterized by recurrent subacute encephalopathy manifest as confusion, seizures, ataxia, dystonia, supranuclear facial palsy, external ophthalmoplegia, and/or dysphagia which - if left untreated - can eventually lead to coma and even death. Dystonia and cogwheel rigidity are nearly always present; hyperreflexia, ankle clonus, and Babinski responses are common. Hemiparesis or quadriparesis may be seen. Episodes are often triggered by febrile illness or mild trauma or surgery. Less frequently, BTBGD presents as chronic or slowly progressive dystonia, seizures, and/or psychomotor delay. Although onset is usually in childhood (ages three to ten 10 years), it is extremely variable, ranging from the newborn period to adulthood. Prompt administration of biotin and thiamine early in the disease course results in partial or complete improvement within days.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Brain MRI shows symmetric and bilateral increased T<sub>2</sub> signal intensity in the central part of caudate head and part or all of the putamen, as well as involvement of the globi pallidi, thalami, infra-and supratentorial brain cortex, brain stem, and cerebellum. During acute crises, severe vasogenic edema can be observed; chronic changes include atrophy, necrosis, and gliosis in the affected regions. The diagnosis of BTBGD is confirmed by identification of biallelic <italic toggle="yes">SLC19A3</italic> pathogenic variants.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Biotin (5-10 mg /kg/day) and thiamine (in doses ranging from 300-900mg) are given orally as early in the disease course as possible and are continued lifelong. Symptoms typically resolve within days. Acute encephalopathic episodes may require care in an ICU to manage seizures and increased intracranial pressure; during acute decompensations thiamine may be increased to double the regular dose and be given intravenously. Treatment of dystonia is symptomatic and includes administration of L-dopa. Rehabilitation, physiotherapy, occupational therapy, and speech therapy as needed. Adaptation of educational programs to meet individual needs.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Prompt administration of biotin and thiamine early in the disease course.</p>
          <p><italic toggle="yes">Surveillance:</italic> Evaluation every six months by the treating subspecialists.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Stress, trauma.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the pathogenic variants have been identified in an affected family member, perform molecular genetic testing on at-risk relatives (e.g., sibs of the proband) in order to begin thiamine and biotin therapy as soon as possible in all individuals with biallelic <italic toggle="yes">SLC19A3</italic> pathogenic variants, even those who are asymptomatic.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Affected women should continue thiamine and biotin during pregnancy.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>BTBGD is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="bgd-biotin.Diagnosis">
        <title>Diagnosis</title>
        <p><bold>Biotin-thiamine-responsive basal ganglia disease (BTBGD) is suspected</bold> in individuals with the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute/subacute encephalopathy with seizures, extra pyramidal manifestations (dystonia, cogwheel rigidity, dysarthria, dysphagia), and pyramidal tract signs (quadriparesis, hyperreflexia) typically in a child age 3-10 years and usually preceded by febrile illness or some other stress. Cerebellar signs, supranuclear facial nerve palsy, external ophthalmoplegia, and ataxia are variably present.</p>
          </list-item>
          <list-item>
            <p>Brain MRI showing the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Bilateral and symmetric increased T<sub>2</sub> signal intensity in the caudate nucleus, putamen, thalamus, infra-and supratentorial brain cortex, and brain stem [<xref ref-type="bibr" rid="bgd-biotin.REF.ozand.1998.1267">Ozand et al 1998</xref>]</p>
              </list-item>
              <list-item>
                <p>Vasogenic edema during acute crises as demonstrated by diffusion-weighted imaging (DWI)/apparent diffusion coefficient (ADC) MRI</p>
              </list-item>
              <list-item>
                <p>Chronic changes including diffuse cerebral cortical and (to a lesser extent) cerebellar atrophy, and gliosis in the affected regions [<xref ref-type="bibr" rid="bgd-biotin.REF.yamada.2010.171">Yamada et al 2010</xref>]</p>
              </list-item>
              <list-item>
                <p>Spinal cord involvement (seen in one affected individual) [<xref ref-type="bibr" rid="bgd-biotin.REF.alfadhel.2013.83">Alfadhel et al 2013</xref>]</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Normal laboratory investigations, including tandem mass spectrometry of blood; urine gas chromatography-mass spectrometry (GC-MS); serum concentrations of lactic acid,* ammonia, biotin, and thiamine; serum biotinidase enzyme activity; urine amino acids; plasma amino acids; liver enzymes; coagulation profile; lipid profile; and cerebrospinal fluid (CSF) cell count, protein, glucose, and cultures* Serum concentration of lactic acid may be high in the acute stage.</p>
          </list-item>
          <list-item>
            <p>Family history consistent with autosomal recessive inheritance. Note: (1) Presumably affected (but undiagnosed) sibs may have had unexplained coma or encephalopathy. (2) To date, consanguinity has been reported in a large portion of families [<xref ref-type="bibr" rid="bgd-biotin.REF.alfadhel.2013.83">Alfadhel et al 2013</xref>, <xref ref-type="bibr" rid="bgd-biotin.REF.tabarki.2013.261">Tabarki et al 2013</xref>].</p>
          </list-item>
        </list>
        <p><bold>Biotin-thiamine-responsive basal ganglia disease (BTBGD) is confirmed</bold> in individuals with biallelic <italic toggle="yes">SLC19A3</italic> pathogenic variants (see <xref ref-type="table" rid="bgd-biotin.T.summary_of_molecular_geneti">Table 1</xref>).</p>
        <p>Sequencing of <italic toggle="yes">SLC19A3</italic> is likely to identify pathogenic variants on both alleles and therefore provide molecular confirmation of BTBGD in most individuals with typical clinical and radiologic findings. Although large exon or whole-gene deletions have not been reported, apparent heterozygosity for a single pathogenic variant in <italic toggle="yes">SLC19A3</italic> identified by sequence analysis in a typically affected individual may indicate compound heterozygosity for a second unidentified pathogenic variant and warrants deletion analysis.</p>
        <table-wrap id="bgd-biotin.T.summary_of_molecular_geneti" position="anchor" orientation="portrait">
          <label>Table 1. </label>
          <caption>
            <p>Summary of Molecular Genetic Testing Used in Biotin-Thiamine-Responsive Basal Ganglia Disease</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                <th id="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                <th id="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>2</sup></th>
                <th id="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">SLC19A3</italic>
                </td>
                <td headers="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup><hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants<hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">42/46&#x000a0;<sup>5</sup><hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon or whole-gene deletions/duplications</td>
                <td headers="hd_h_bgd-biotin.T.summary_of_molecular_geneti_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported&#x000a0;<sup>7</sup></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="bgd-biotin.TF.1.1">
              <label>1. </label>
              <p>See <related-object source-id="gene" document-id="bgd-biotin" object-id="bgd-biotin.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
            </fn>
            <fn id="bgd-biotin.TF.1.2">
              <label>2. </label>
              <p>See <xref ref-type="sec" rid="bgd-biotin.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
            </fn>
            <fn id="bgd-biotin.TF.1.3">
              <label>3. </label>
              <p>The ability of the test method used to detect a pathogenic variant that is present in the indicated gene</p>
            </fn>
            <fn id="bgd-biotin.TF.1.4">
              <label>4. </label>
              <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
            </fn>
            <fn id="bgd-biotin.TF.1.5">
              <label>5. </label>
              <p><xref ref-type="bibr" rid="bgd-biotin.REF.zeng.2005.16">Zeng et al [2005]</xref>, <xref ref-type="bibr" rid="bgd-biotin.REF.debs.2010.126">Debs et al [2010]</xref>, <xref ref-type="bibr" rid="bgd-biotin.REF.tabarki.2013.261">Tabarki et al [2013]</xref></p>
            </fn>
            <fn id="bgd-biotin.TF.1.6">
              <label>6. </label>
              <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
            </fn>
            <fn id="bgd-biotin.TF.1.7">
              <label>7. </label>
              <p>No deletions or duplications involving <italic toggle="yes">SLC19A3</italic> have been reported to cause BTBGD.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="bgd-biotin.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="bgd-biotin.Clinical_Description">
          <title>Clinical Description</title>
          <p>Biotin-thiamine-responsive basal ganglia disease (BTBGD) usually presents in children of preschool age or early school age (i.e., ages 3-10 years). In one report onset was at age one month [<xref ref-type="bibr" rid="bgd-biotin.REF.p_rezdue_as.2013">P&#x000e9;rez-Due&#x000f1;as et al 2013</xref>] and in another at age 20 years [<xref ref-type="bibr" rid="bgd-biotin.REF.debs.2010.126">Debs et al 2010</xref>].</p>
          <p>Most commonly BTBGD is characterized by recurrent subacute onset of encephalopathy manifest as confusion, generalized seizures, ataxia, dystonia, supranuclear facial palsy, external ophthalmoplegia, and dysphagia, eventually leading to coma and even death. This encephalopathy may be associated with variable degree of raised intracranial pressure. Dystonia and cogwheel rigidity are nearly always present. Hyperreflexia, ankle clonus, and Babinski responses are common. Hemiparesis or quadriparesis may be seen. Episodes are often triggered by febrile illness, mild trauma, or stress.</p>
          <p>Less frequently, BTBGD presents as a chronic or slowly progressive condition characterized by dystonia, seizures, and psychomotor delay.</p>
          <p>Seizures are mainly simple partial or generalized seizures and are easily controlled with antiepileptic drugs. Infantile spasms also occur [<xref ref-type="bibr" rid="bgd-biotin.REF.yamada.2010.171">Yamada et al 2010</xref>].</p>
          <p>Administration of biotin and thiamine early in the disease course results in partial or complete clinical improvement within days (see <xref ref-type="sec" rid="bgd-biotin.Management">Management</xref>). Lifelong treatment is required. Treatment initiated later in the disease course or lack of treatment may result in death or chronic neurologic sequelae including dystonia, quadriparesis, epilepsy, or mild intellectual disability may ensue.</p>
        </sec>
        <sec id="bgd-biotin.Prevalence">
          <title>Prevalence</title>
          <p>Prevalence is unknown.</p>
          <p>The disease is pan ethnic; however, it is most prevalent in Saudi Arabia.</p>
        </sec>
        <sec id="bgd-biotin.GenotypePhenotype_Correlation">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype-phenotype correlations are poor. Despite having the same pathogenic variants, children from the same family have extremely variable outcomes, ranging from normal to severely handicapped [<xref ref-type="bibr" rid="bgd-biotin.REF.alfadhel.2013.83">Alfadhel et al 2013</xref>].</p>
        </sec>
      </sec>
      <sec id="bgd-biotin.Genetically_Related_Allelic_D">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Compound heterozygous <italic toggle="yes">SLC19A3</italic> pathogenic variants (<xref ref-type="table" rid="bgd-biotin.T.slc19a3_pathogenic_allelic">p.Lys44Glu</xref>, <xref ref-type="table" rid="bgd-biotin.T.slc19a3_pathogenic_allelic">p.Glu320Gln</xref>) have been associated with Wernicke-like encephalopathy, characterized by acute onset of epilepsy, ataxia, nystagmus, and ophthalmoplegia in the second decade of life [<xref ref-type="bibr" rid="bgd-biotin.REF.kono.2009.1792">Kono et al 2009</xref>].</p>
        <p>Homozygosity for the <italic toggle="yes">SLC19A3</italic> pathogenic variant c.958 G&#x0003e;C (p.Glu320Gln) causes epileptic seizures in early infancy, severe psychomotor retardation, and characteristic findings on brain MRI of progressive brain atrophy and bilateral thalamic and basal ganglia alterations in signal intensity.</p>
        <p>Early-infantile, lethal encephalopathy caused by pathogenic variants in <italic toggle="yes">SLC19A3</italic> has been reported [<xref ref-type="bibr" rid="bgd-biotin.REF.kevelam.2013.1534">Kevelam et al 2013</xref>]<italic toggle="yes">.</italic></p>
        <p>Early-childhood fatal Leigh syndrome caused by novel pathogenic variant in <italic toggle="yes">SLC19A3</italic> has been reported [<xref ref-type="bibr" rid="bgd-biotin.REF.gerards.2013.882">Gerards et al 2013</xref>]<italic toggle="yes">.</italic></p>
      </sec>
      <sec id="bgd-biotin.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Additional disorders in the differential diagnosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Wernicke encephalopathy</p>
          </list-item>
          <list-item>
            <p>Organic acid disorders</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial disorders</related-object> (including Leigh syndrome)</p>
          </list-item>
          <list-item>
            <p>Toxic encephalopathy</p>
          </list-item>
          <list-item>
            <p>Infectious encephalopathy</p>
          </list-item>
          <list-item>
            <p>Inflammatory disease (including CNS vasculitis)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="wilson" document-type="chapter">Wilson disease</related-object>&#x000a0;*</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Juvenile Huntington disease</related-object>
            </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="xdp" document-type="chapter">Torsion dystonia</related-object> (DYT1)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="thdrd" document-type="chapter">Dopa-responsive dystonia</related-object>&#x000a0;*</p>
          </list-item>
          <list-item>
            <p>Acute disseminated encephalomyelitis (ADEM)</p>
            <list list-type="bullet">
              <list-item>
                <label>*</label>
                <p>Dopa-responsive dystonia and Wilson disease are important to consider because they are treatable.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>In its chronic stage BTBGD shares clinical features with several conditions including <related-object link-type="booklink" source-id="gene" document-id="wilson" document-type="chapter">Wilson disease</related-object>, <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">juvenile Huntington disease</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="xdp" document-type="chapter">torsion dystonia</related-object> (DYT1); however, BTBGD can be differentiated by its acute to subacute presentation.</p>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/phenotypicSeries/PS249270">Thiamine-responsive dysfunction syndrome: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="bgd-biotin.Management">
        <title>Management</title>
        <sec id="bgd-biotin.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with biotin-thiamine responsive basal ganglia disease (BTBGD), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic evaluation by a pediatric neurologist</p>
            </list-item>
            <list-item>
              <p>Assessments by specialists in rehabilitation medicine, physiotherapy, occupational therapy, and speech therapy</p>
            </list-item>
            <list-item>
              <p>Psychology evaluation for assessment of IQ</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="bgd-biotin.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Appropriate treatment includes the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>ICU care during acute encephalopathic episode, including treatment of seizures and increased intracranial pressure</p>
            </list-item>
            <list-item>
              <p>Biotin and thiamine therapy. Biotin is given as 5-10 mg /kg and thiamine as 300-900 mg orally. (Note: In one report 20mg/kg/day in a neonate was used.)
Symptoms typically resolve within days. (Note: <italic toggle="yes">SLC19A3</italic> encodes a second thiamine transport and some patients respond only to thiamine.)</p>
              <list list-type="bullet">
                <list-item>
                  <p>Biotin and thiamine need to be given lifelong.</p>
                </list-item>
                <list-item>
                  <p>During acute decompensation thiamine may be increased to double the regular dose and given intravenously.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In the acute stage empiric treatment with antimicrobial/antiviral agents. Recommended until infectious causes of the acute/subacute encephalopathy are ruled out.</p>
            </list-item>
            <list-item>
              <p>Fever control. Paramount as fever downregulates <italic toggle="yes">SLC19A3</italic> and may exacerbate the disease.</p>
            </list-item>
            <list-item>
              <p>Antiepileptic drugs for effective control of seizures</p>
            </list-item>
            <list-item>
              <p>Symptomatic treatment of dystonia, including administration of L-dopa</p>
            </list-item>
            <list-item>
              <p>Rehabilitation, physiotherapy, occupational therapy, and speech therapy</p>
            </list-item>
            <list-item>
              <p>Educational programs adapted to individual needs</p>
            </list-item>
            <list-item>
              <p>Education of the family regarding the importance of lifelong compliance with medical therapy</p>
            </list-item>
          </list>
        </sec>
        <sec id="bgd-biotin.Prevention_of_Primary_Manifes">
          <title>Prevention of Primary Manifestations</title>
          <p>Appropriate measures include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Prompt administration of biotin and thiamine early in the disease course (see <xref ref-type="sec" rid="bgd-biotin.Treatment_of_Manifestations">Treatment of Manifestations</xref>)</p>
            </list-item>
            <list-item>
              <p>Avoidance of triggers/stressors including trauma and surgery</p>
            </list-item>
          </list>
        </sec>
        <sec id="bgd-biotin.Surveillance">
          <title>Surveillance</title>
          <p>Evaluation every six months by the treating subspecialists (pediatric neurologist, metabolic genetic specialist, physiotherapist, and psychologists) is appropriate.</p>
        </sec>
        <sec id="bgd-biotin.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Stress and trauma should be avoided as they can precipitate acute attacks.</p>
        </sec>
        <sec id="bgd-biotin.Evaluation_of_Relatives_at_Ri">
          <title>Evaluation of Relatives at Risk</title>
          <p>If the pathogenic variants have been identified in an affected family member, perform molecular genetic testing on at-risk relatives (e.g., sibs of the proband) in order to begin biotin and thiamine therapy as soon as possible in all individuals with biallelic <italic toggle="yes">SLC19A3</italic> pathogenic variants, even those who are asymptomatic.</p>
          <p>See <xref ref-type="sec" rid="bgd-biotin.Related_Genetic_Counseling_Is">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="bgd-biotin.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Affected women should continue biotin and thiamine therapy during pregnancy. No information regarding risk to the fetus of an affected mother is available.</p>
        </sec>
        <sec id="bgd-biotin.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="bgd-biotin.Other">
          <title>Other</title>
          <p>Routine administration of immunizations is recommended (without any specific precautions).</p>
        </sec>
      </sec>
      <sec id="bgd-biotin.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="bgd-biotin.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Biotin-thiamine-responsive basal ganglia disease (BTBGD) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="bgd-biotin.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Unless an individual with BTBGD has children with an affected individual or a carrier, his/her offspring will be obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">SLC19A</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="bgd-biotin.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
        </sec>
        <sec id="bgd-biotin.Related_Genetic_Counseling_Is">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="bgd-biotin.Evaluation_of_Relatives_at_Ri">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="bgd-biotin.Prenatal_Testing_and_Preimpla">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">SLC19A3</italic> pathogenic variants have been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for BTBGD are possible options.</p>
          <p>Requests for prenatal testing for conditions which (like BTBGD) have treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="bgd-biotin.Resources">
        <title>Resources</title>
      </sec>
      <sec id="bgd-biotin.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">SLC19A3</italic> spans 32.91 kb of genomic DNA, and consists of six exons with a start codon in exon 2 and a TAA stop codon in exon 6. <italic toggle="yes">SLC19A3</italic> is a member of the SLC19 (solute carrier family 19) gene family (comprising <italic toggle="yes">SLC19A1</italic>, <italic toggle="yes">SLC19A2</italic>, and <italic toggle="yes">SLC19A3</italic>) that is responsible for the uptake of water-soluble vitamins into cells. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bgd-biotin" object-id="bgd-biotin.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold>
<italic toggle="yes">SLC19A3</italic> pathogenic variants described in persons with BTBGD include the following (in decreasing order of frequency): c.1264A&#x0003e;G, c.68G&#x0003e;T, c.74dupT, c.980-38dupA, and c.980-14A&#x0003e;G [<xref ref-type="bibr" rid="bgd-biotin.REF.zeng.2005.16">Zeng et al 2005</xref>, <xref ref-type="bibr" rid="bgd-biotin.REF.debs.2010.126">Debs et al 2010</xref>, <xref ref-type="bibr" rid="bgd-biotin.REF.alfadhel.2013.83">Alfadhel et al 2013</xref>, <xref ref-type="bibr" rid="bgd-biotin.REF.tabarki.2013.261">Tabarki et al 2013</xref>].</p>
        <table-wrap id="bgd-biotin.T.slc19a3_pathogenic_allelic" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p><italic toggle="yes">SLC19A3</italic> Pathogenic Allelic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.68G&#x0003e;T<hr/></td>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly23Val<hr/></td>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_3" rowspan="7" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_025243.3">NM_025243.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_079519.1">NP_079519.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.74dupT<hr/></td>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser26LeufsTer19<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.130A&#x0003e;G<break/>(218A&#x0003e;G)<hr/></td>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Lys44Glu<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.958G&#x0003e;C<break/>(1047G&#x0003e;C)<hr/></td>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu320Gln<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.980-38dupA<hr/></td>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.980-14A&#x0003e;G<hr/></td>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1264A&#x0003e;G</td>
                <td headers="hd_h_bgd-biotin.T.slc19a3_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr422Ala</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="bgd-biotin.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="bgd-biotin.T.summary_of_pathogenic_genot" position="anchor" orientation="portrait">
          <label>Table 3. </label>
          <caption>
            <p>Summary of Pathogenic Genotypes Reported in BTBGD</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Location</th>
                <th id="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">SLC19A3</italic> Genotypes</th>
                <th id="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Number of Individuals</th>
                <th id="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Ethnicity</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Exon 5<hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.[1264A&#x0003e;G];[1264A&#x0003e;G]&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">38<hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Saudi<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Exon 3<hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.[958G&#x0003e;C ];[958G&#x0003e;C]&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">4<hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Japanese<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Exon 2<hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.[68G&#x0003e;T];[68G&#x0003e;T]&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3<hr/></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Yemeni, Moroccan<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Exon 2 and intron 3</td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.[74dupT];[980-14A&#x0003e;G]&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2</td>
                <td headers="hd_h_bgd-biotin.T.summary_of_pathogenic_genot_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Portuguese</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="bgd-biotin.TF.3.1">
              <label>1. </label>
              <p>Homozygous</p>
            </fn>
            <fn id="bgd-biotin.TF.3.2">
              <label>2. </label>
              <p>Compound heterozygous</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">SLC19A3</italic> encodes thiamine transporter 2 (hTHTR2).</p>
        <p><bold>Abnormal gene product.</bold> The mechanism of action of biotin remains unclear. The absence of deficient serum concentrations of biotin and thiamine and the efficacy of high doses of biotin in the treatment of biotin-thiamine-responsive basal ganglia disease (BTBGD) [<xref ref-type="bibr" rid="bgd-biotin.REF.ozand.1998.1267">Ozand et al 1998</xref>, <xref ref-type="bibr" rid="bgd-biotin.REF.subramanian.2006.c851">Subramanian et al 2006</xref>] suggest that high doses of biotin increase expression of hTHTR2, thus restoring some function of the mutated receptor. On the other hand, the new understanding of the function of <italic toggle="yes">SCL19A3</italic> highlights the major role of thiamine in the treatment of BTBGD.</p>
      </sec>
      <sec id="bgd-biotin.References">
        <title>References</title>
        <sec id="bgd-biotin.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="bgd-biotin.Literature_Cited.reflist0">
            <ref id="bgd-biotin.REF.alfadhel.2013.83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alfadhel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almuntashri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jadah</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bashiri</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Rifai</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Shalaan</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Balwi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Rumayan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eyaid</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Twaijri</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>83</fpage>
                <pub-id pub-id-type="pmid">23742248</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.debs.2010.126">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Debs</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Depienne</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rastetter</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellanger</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Degos</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galanaud</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keren</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyon-Caen</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sedel</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations.</article-title>
                <source>Arch Neurol.</source>
                <year>2010</year>
                <volume>67</volume>
                <fpage>126</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">20065143</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.gerards.2013.882">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gerards</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamps</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Oevelen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boesten</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jongen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Koning</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholte</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Angst</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoonderwoerd</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sefiani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ratbi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coppieters</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karim</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Coo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Bosch</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeets</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome.</article-title>
                <source>Brain.</source>
                <year>2013</year>
                <volume>136</volume>
                <fpage>882</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">23423671</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.kevelam.2013.1534">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kevelam</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bugiani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feigenbaum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaser</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000e4;berle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baric</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakker</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Postma</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanhai</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>NI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abbink</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waisfisz</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heutink</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <article-title>Exome sequencing reveals mutated SLC19A3 in patients with an early-infantile, lethal encephalopathy.</article-title>
                <source>Brain.</source>
                <year>2013</year>
                <volume>136</volume>
                <fpage>1534</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">23482991</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.kono.2009.1792">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Togawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shirakawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in a thiamine-transporter gene and Wernicke&#x02019;s-like encephalopathy.</article-title>
                <source>N Engl J Med</source>
                <year>2009</year>
                <volume>360</volume>
                <fpage>1792</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19387023</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.ozand.1998.1267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ozand</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gascon</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Essa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joshi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Jishi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakheet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Watban</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Kawi</surname>
                    <given-names>MZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dabbagh</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Biotin-responsive basal ganglia disease: a novel entity.</article-title>
                <source>Brain.</source>
                <year>1998</year>
                <volume>121</volume>
                <fpage>1267</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">9679779</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.p_rezdue_as.2013">
              <mixed-citation publication-type="other">P&#x000e9;rez-Due&#x000f1;as B, Serrano M, Rebollo M, Muchart J, Gargallo E, Dupuits C, Artuch R. Reversible lactic acidosis in a newborn with thiamine transporter-2 deficiency. Pediatrics. 2013;131:e1670-5.</mixed-citation>
            </ref>
            <ref id="bgd-biotin.REF.subramanian.2006.c851">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Subramanian</surname>
                    <given-names>VS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchant</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>HM</given-names>
                  </name>
                </person-group>
                <article-title>Biotin-responsive basal ganglia disease-linked mutations inhibit thiamine transport via hTHTR2: biotin is not a substrate for hTHTR2.</article-title>
                <source>Am J Physiol Cell Physiol.</source>
                <year>2006</year>
                <volume>291</volume>
                <fpage>C851</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16790503</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.tabarki.2013.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tabarki</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Shafi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Shahwan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azmat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Hashem</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Al-Adwani, Biary N, Al-Zawahmah M, Khan S, Zuccoli G. Biotin-responsive basal ganglia disease revisited: clinical, neuroradiological, and genetic findings.</article-title>
                <source>Neurology</source>
                <year>2013</year>
                <volume>80</volume>
                <fpage>261</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23269594</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.yamada.2010.171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakanishi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumagai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishihara</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuwano</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakamatsu</surname>
                    <given-names>N.</given-names>
                  </name>
                </person-group>
                <article-title>A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations.</article-title>
                <source>BMC Med Genet.</source>
                <year>2010</year>
                <volume>11</volume>
                <fpage>171</fpage>
                <pub-id pub-id-type="pmid">21176162</pub-id>
              </element-citation>
            </ref>
            <ref id="bgd-biotin.REF.zeng.2005.16">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zeng</surname>
                    <given-names>WQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Yamani</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acierno</surname>
                    <given-names>JS</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Slaugenhaupt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillis</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozand</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gusella</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <article-title>Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2005</year>
                <volume>77</volume>
                <fpage>16</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">15871139</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="bgd-biotin.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="bgd-biotin.Acknowledgments">
          <title>Acknowledgments</title>
          <p>We would like to thank Dr S Al Shafi Shatha and Dr Saad Al Shahwan, Division of Pediatric Neurology, PSMMC.</p>
        </sec>
        <sec id="bgd-biotin.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>21 November 2013 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>28 May 2013 (aah) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
